Locations:
Search
Rebound risk is shaped by patient characteristics and mechanism of action of current DMT
First-of-kind prediction model demonstrates high consistency across internal and external validation
Real-world study also finds no significant rise in ocrelizumab-related risk with advanced age
Machine learning study associates discrete neuropsychological testing profiles with neurodegeneration
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Despite less overall volume loss than in MS and NMOSD, volumetric changes correlate with functional decline
This MRI marker of inflammation can help differentiate MS from mimics early in the disease
Focuses include real-world research, expanding access and more
Case-control study yields evidence of epigenetic aging in pediatric-onset MS
Novel insights from a postmortem study combining imaging, pathology and clinical perspectives
Long-awaited efficacy against disability progression in nonrelapsing SPMS appears to be at hand
Advertisement
Advertisement